High-dose, short-interval daptomycin regimen was safe and well tolerated in three patients with chronic renal failure
Authors Yabuno K, Seki M, Miyawaki K, Miwa Y, Tomono K
Received 28 August 2013
Accepted for publication 3 October 2013
Published 5 November 2013 Volume 2013:5(1) Pages 161—166
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 4
Kaori Yabuno,1,2,* Masafumi Seki,1,* Koji Miyawaki,1,2 Yoshihiro Miwa,2 Kazunori Tomono1
1Division of Infection Control and Prevention, 2Department of Pharmacy, Osaka University Hospital, Osaka, Japan
*These authors contributed equally to this work
Background: The recommended daptomycin dosage is 4 or 6 mg/kg/day for the treatment of complicated skin and soft tissue infections or for Staphylococcus aureus bacteremia, endocarditis, and osteomyelitis. Every other day administration is usually recommended for patients with mild to moderate renal impairment. Higher doses (>6 mg/kg/day) have been explored as a possible alternative. Daptomycin is considered a safe anti-methicillin-resistant S. aureus (MRSA) drug, although renal dysfunction may be worsened. In this paper we report on three patients with chronic renal failure who received a higher dose of daptomycin daily for successful treatment for MRSA bacteremia, MRSA osteomyelitis, and methicillin-resistant S. epidermidis (MRSE) endocarditis.
Results: Previous administration of other drugs, including vancomycin, teicoplanin, and linezolid, had failed. In spite of daily treatment with daptomycin instead of the recommended alternate day regimen, adverse effects, such as elevation of creatinine and creatine phosphokinase, did not occur.
Conclusion: These experiences suggest that administration of high-dose/short-interval daptomycin can be efficient and safe even in the setting of renal dysfunction, and should be considered for the treatment of severe MRSA/MRSE infections in these patients.
Keywords: daptomycin, high-dose, renal failure, methicillin-resistant Staphylococcus aureus, creatine phosphokinase
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF] View Full Text [HTML][Machine readable]